Imugene Ltd has garnered fast track designation from the US Food and Drug Administration (FDA) for its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel), in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Transformative potential
“Receiving FDA Fast Track Designation is a testament to the transformative potential of azer-cel for patients battling relapsed or refractory DLBCL,” Imugene CEO and MD Leslie Chong said.
“We are committed to working closely with the FDA to bring this important therapy to patients as efficiently as possible.”
The fast track designation has the purpose of accelerating the development and regulatory review of therapies that address serious or life-threatening conditions with high unmet medical need.
This status provides Imugene with access to more frequent FDA interactions, rolling submission reviews and potential eligibility for Accelerated Approval and Priority Review.
A next-generation CAR T therapy
Azer-cel is an off-the-shelf, CD19-directed CAR T-cell therapy engineered to overcome the manufacturing and accessibility limitations of autologous CAR T therapies.
By using pre-manufactured donor T-cells, azer-cel enables faster treatment delivery for patients who require urgent intervention.
Clinical data from the ongoing Phase 1b trial has demonstrated promising results, particularly in patients who have failed multiple prior treatments, including autologous CAR T therapy.
The therapy employs a novel combination of lymphodepletion chemotherapy and interleukin-2 (IL-2) to enhance CAR T-cell persistence and efficacy.
To date, azer-cel has exhibited a manageable safety profile, with no reported cases of immune effector cell-associated neurotoxicity syndrome (ICANS) in key patient cohorts.
Critical need in aggressive blood cancer
DLBCL is the most common and aggressive form of non-Hodgkin’s lymphoma, with many patients experiencing relapse or resistance to standard treatments.
Azer-cel aims to provide a novel therapeutic approach for these patients, offering a potentially more accessible and effective treatment option.
With Fast Track status, Imugene is well-positioned to accelerate azer-cel’s clinical development, working closely with the FDA to bring the therapy to market as efficiently as possible.
This designation reinforces azer-cel’s potential as a transformative treatment for patients battling relapsed or refractory DLBCL.